Evaluation of anti-citrullinated and anti-carbamylated antibodies in mexicans with rheumatoid arthritis and at-risk individuals.

Edgar E Lara-Ramírez, Betzaida Cuevas-Córdoba, Diana Olguín-Calderon, Yadira Bastian, César Ramos-Remus, José D Castillo-Ortiz, Martín Zapata-Zúñiga, Jesús Núñez-Contreras, Leendert A Trouw, José A Enciso-Moreno, Julio E Castañeda-Delgado
{"title":"Evaluation of anti-citrullinated and anti-carbamylated antibodies in mexicans with rheumatoid arthritis and at-risk individuals.","authors":"Edgar E Lara-Ramírez, Betzaida Cuevas-Córdoba, Diana Olguín-Calderon, Yadira Bastian, César Ramos-Remus, José D Castillo-Ortiz, Martín Zapata-Zúñiga, Jesús Núñez-Contreras, Leendert A Trouw, José A Enciso-Moreno, Julio E Castañeda-Delgado","doi":"10.24875/RIC.24000181","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) diagnosis is a challenge in the initial phases of the disease when clinical symptoms are only starting to develop. Early diagnosis and treatment can promote long-term remission, reduce disability, and improve cardiovascular outcomes. Autoantibodies can help in the diagnosis and identification of RA patients in the early phases of the disease, but scarce information has been reported for the Mexican population.</p><p><strong>Objective: </strong>To study anti-citrullinated peptide antibodies (anti-CCP) and anti-carbamylated protein antibodies (anti-CarP) in Mexican patients with RA and individuals at high risk of developing the disease.</p><p><strong>Methods: </strong>Serum samples from long-standing and early RA patients, first-degree relatives (FstD) of RA patients, and healthy individuals were analyzed for anti-CCP and anti-CarP using enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Anti-CCP and anti-CarP levels were higher in the RA groups than in the FstD and healthy groups. The odds ratio (OR) for antiCCP for RA groups was 29.7 (95% confidence interval [CI] 14.2-61.9), significantly higher than the OR for anti-CarP 11.07 (95% CI 5.4-22.8). The sensitivity of anti-CCP was 85% (95% CI 76-93) higher than for anti-CarP (42.1%, 95% CI 31-54). The specificity of anti-CarP was 93.8% (95% CI 90-97) and the specificity of anti-CCP was 83.4% (95% CI 78-88). Using both tests in parallel increased sensitivity to 91%, while a sequential approach increased sensitivity to 98%.</p><p><strong>Conclusion: </strong>Anti-CCP outperformed anti-CarP in Mexican RA patients, demonstrating greater sensitivity, while anti-CarP showed higher specificity. Combining these tests, either simultaneously or sequentially, could enhance diagnostic accuracy. (.</p>","PeriodicalId":49612,"journal":{"name":"Revista De Investigacion Clinica-Clinical and Translational Investigation","volume":"76 6","pages":"243-252"},"PeriodicalIF":1.4000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista De Investigacion Clinica-Clinical and Translational Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.24875/RIC.24000181","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Rheumatoid arthritis (RA) diagnosis is a challenge in the initial phases of the disease when clinical symptoms are only starting to develop. Early diagnosis and treatment can promote long-term remission, reduce disability, and improve cardiovascular outcomes. Autoantibodies can help in the diagnosis and identification of RA patients in the early phases of the disease, but scarce information has been reported for the Mexican population.

Objective: To study anti-citrullinated peptide antibodies (anti-CCP) and anti-carbamylated protein antibodies (anti-CarP) in Mexican patients with RA and individuals at high risk of developing the disease.

Methods: Serum samples from long-standing and early RA patients, first-degree relatives (FstD) of RA patients, and healthy individuals were analyzed for anti-CCP and anti-CarP using enzyme-linked immunosorbent assay.

Results: Anti-CCP and anti-CarP levels were higher in the RA groups than in the FstD and healthy groups. The odds ratio (OR) for antiCCP for RA groups was 29.7 (95% confidence interval [CI] 14.2-61.9), significantly higher than the OR for anti-CarP 11.07 (95% CI 5.4-22.8). The sensitivity of anti-CCP was 85% (95% CI 76-93) higher than for anti-CarP (42.1%, 95% CI 31-54). The specificity of anti-CarP was 93.8% (95% CI 90-97) and the specificity of anti-CCP was 83.4% (95% CI 78-88). Using both tests in parallel increased sensitivity to 91%, while a sequential approach increased sensitivity to 98%.

Conclusion: Anti-CCP outperformed anti-CarP in Mexican RA patients, demonstrating greater sensitivity, while anti-CarP showed higher specificity. Combining these tests, either simultaneously or sequentially, could enhance diagnostic accuracy. (.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估抗瓜氨酸和抗氨基甲酰化抗体在墨西哥与类风湿关节炎和高危个体。
背景:类风湿性关节炎(RA)的诊断是一个挑战,在疾病的初期阶段,临床症状才刚刚开始发展。早期诊断和治疗可以促进长期缓解,减少残疾,改善心血管预后。自身抗体可以帮助RA患者在疾病的早期阶段进行诊断和鉴定,但关于墨西哥人群的信息报道很少。目的:研究墨西哥RA患者及RA高危人群的抗瓜氨酸肽抗体(anti-CCP)和抗氨基甲酰化蛋白抗体(anti-CarP)水平。方法:采用酶联免疫吸附法对长期和早期RA患者、RA患者一级亲属(FstD)和健康人的血清进行抗ccp和抗carp检测。结果:RA组抗ccp和抗carp水平高于FstD组和健康组。RA组anticp的比值比(OR)为29.7(95%可信区间[CI] 14.2-61.9),显著高于anti-CarP的比值比11.07 (95% CI 5.4-22.8)。抗ccp敏感性为85% (95% CI 76-93),高于抗carp敏感性(42.1%,95% CI 31-54)。抗鲤鱼特异性为93.8% (95% CI 90-97),抗ccp特异性为83.4% (95% CI 78-88)。同时使用两种测试可将灵敏度提高到91%,而顺序方法可将灵敏度提高到98%。结论:在墨西哥RA患者中,Anti-CCP优于anti-CarP,具有更高的敏感性,而anti-CarP具有更高的特异性。将这些测试同时或依次结合起来,可以提高诊断的准确性。(.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.00
自引率
0.00%
发文量
60
审稿时长
>12 weeks
期刊介绍: The Revista de Investigación Clínica – Clinical and Translational Investigation (RIC-C&TI), publishes original clinical and biomedical research of interest to physicians in internal medicine, surgery, and any of their specialties. The Revista de Investigación Clínica – Clinical and Translational Investigation is the official journal of the National Institutes of Health of Mexico, which comprises a group of Institutes and High Specialty Hospitals belonging to the Ministery of Health. The journal is published both on-line and in printed version, appears bimonthly and publishes peer-reviewed original research articles as well as brief and in-depth reviews. All articles published are open access and can be immediately and permanently free for everyone to read and download. The journal accepts clinical and molecular research articles, short reports and reviews. Types of manuscripts: – Brief Communications – Research Letters – Original Articles – Brief Reviews – In-depth Reviews – Perspectives – Letters to the Editor
期刊最新文献
The relationship between liver enzymes in the blood test and non-fatal cardiovascular disease events: a systematic review and meta-analysis. MicroRNA-138-2-3p inhibits cell migration, invasion and EMT process in non-small-cell lung cancer by targeting antizyme inhibitor 1. Cinnamic acid ameliorates platelet activating factor-induced airway epithelial cell apoptosis and inflammation by inhibiting TGF-β1/Smad signaling pathway in an in vitro model of asthma. Diagnostic and prognostic significance of IL-18 and its -607C/A polymorphism in COVID-19: Implications for CURB-65 severity scoring. Optimizing glioma vascular analysis: A finetuned masked autoencoder self-attention mechanism approach for accurate and interactive blood vessel segmentation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1